MABC539
抗-SFRP2抗体，克隆80.8.6，不含叠氮化物
clone 80.8.6, from mouse
别名:
Secreted frizzled-related protein 2, FRP-2, sFRP-2, Secreted apoptosis-related protein 1, SARP-1
登录 查看组织和合同定价。
选择尺寸
关于此项目
UNSPSC Code:
12352203
NACRES:
NA.41
eCl@ss:
32160702
Conjugate:
unconjugated
Clone:
80.8.6, monoclonal
Application:
IHC, inhibition assay
Citations:
3
biological source
mouse
conjugate
unconjugated
antibody form
purified antibody
antibody product type
primary antibodies
clone
80.8.6, monoclonal
species reactivity
human
technique(s)
immunohistochemistry: suitable, inhibition assay: suitable
isotype
IgG2aκ
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Quality Level
Gene Information
human ... SFRP2(6423)
General description
分泌型卷曲相关蛋白（SFRP）通过抑制Wnt/β-连环蛋白信号传导通路，可能在癌症发生中起关键作用。分泌型卷曲相关蛋白2（SFRP2）可用于研究乳腺肿瘤发生，因为在犬乳腺肿瘤中其表达随肿瘤的进展增加。研究发现小鼠胚胎中的SFRP2导致胸区严重变短。研究表明该蛋白是必需的干细胞旁分泌因子，该因子被认为是可以在缺血性损伤后调节心肌存活并修复损伤。
计算分子量为33 kDa
Immunogen
KLH偶联的线性肽，对应于人SFRP2的NTR结构域。
表位：NTR 结构域
Application
抑制分析：抗-SFRP2（克隆80.8.6）抗体在体外抑制小管形成和SVR 血管肉瘤细胞的迁移，在体内抑制血管肉瘤和乳腺癌生长，并提高细胞核NFATc3水平。
抗-SFRP2抗体（克隆80.8.6, 不含叠氮化物）是一种针对SFRP2 的抗体，用于 IHC &抑制。
Physical form
形式：纯化
Analysis Note
通过免疫组化在人前列腺和人乳腺癌组织中进行了评估。
免疫组化分析：该抗体的1：500稀释液在人前列腺和人乳腺癌组织中检测到SFRP2。
免疫组化分析：该抗体的1：500稀释液在人前列腺和人乳腺癌组织中检测到SFRP2。
Other Notes
浓度：请参考批次特异性浓缩物的检验报告。
未找到合适的产品？
试试我们的产品选型工具.
存储类别
12 - Non Combustible Liquids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Mitchell E Fane et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 26(21), 5709-5719 (2020-10-25)
Angiogenesis is thought to be critical for tumor metastasis. However, inhibiting angiogenesis using antibodies such as bevacizumab (Avastin), has had little impact on melanoma patient survival. We have demonstrated that both angiogenesis and metastasis are increased in older individuals, and
Amanpreet Kaur et al.
Nature, 532(7598), 250-254 (2016-04-05)
Cancer is a disease of ageing. Clinically, aged cancer patients tend to have a poorer prognosis than young. This may be due to accumulated cellular damage, decreases in adaptive immunity, and chronic inflammation. However, the effects of the aged microenvironment
Y Sun et al.
Oncogene, 35(33), 4321-4334 (2016-01-12)
Most tumors initially respond to cytotoxic treatments, but acquired resistance often follows. The tumor microenvironment (TME) is a major barrier to clinical success by compromising therapeutic efficacy, and pathological relevance of multiple soluble factors released by a therapeutically remodeled TME
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持